Skip to main content

Regulus Therapeutics Inc.

RGLSDelisted Jun 25, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001505512

Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.

Q1 2022 vs. Q4 2021

How the institutions holding Regulus Therapeutics Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of RGLS: Q4 2021 compared with Q1 2022
MeasureQ4 2021Of which not filed for Q1 2022Q1 2022Change
Holders381370
Shares30.2M2.73M60.7M+33.2M (+121.1%)
Value$9.54M$860.0K$18.1M+$9.40M (+108.3%)

1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held Regulus Therapeutics Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to RGLS in Q1 2022
InstitutionSharesValue% of portfolio
Federated Hermes, Inc.29,048,265$8.66M0.02%
Susquehanna International Group, LLP65,825$20.0K0.00%
Millennium Management LLC48,886$15.0K0.00%

Sold out (3)

Institutions that held Regulus Therapeutics Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of RGLS in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Empery Asset Management, LP5,074,251$1.60M
Morgan Stanley6,000$2.00K
Simplex Trading, LLC1,049$0

Not filed for Q1 2022 yet (1)

Institutions that held Regulus Therapeutics Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding RGLS in Q4 2021 that haven't filed for Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Asymmetry Capital Management, L.P.2,731,044$860.0K